Treatment of Hepatitis C has remarkably changed worldwide with the introduction of Directly Acting Agents (DAA’s). Multiple regimens have been employed for the treatment of hepatitis C patients. In 2018, the regimen of sofosbuvir and velpatasvir (SOF/VEL) was approved by World Health Organization to be used.The aim of this study was to assess the efficacy of SOF/VEL in the treatment of chronic hepatitis C patients in a tertiary care hospital in Pakistan.  Materials and Methods This was a prospective and single arm interventional study conducted from July 2021 to July 2022 at Holy Family Hospital, Rawalpindi after getting ethical approval from Rawalpindi Medical University. Chronic hepatitis C patients regardless of having complications such as hepatocellular carcinoma, decompensated liver disease and previous treatment history were recruited after taking informed consent. All patients were give single tablet combination of SOF/VEL for period of 12 weeks after which sustained virological response (SVR) was measured. Data were collected on a structured proforma and was entered and analyzed in IBM SPSS 23.0.

Keywords : Sofosbuvir, Velpatasvir, Hepatitis C, sustained virological response, Pakistan.